Table 2.
Rates and incidence ratios of asthma exacerbations and admissions during control and exposure intervals.
| Rate per 100 person-y |
Incidence ratioa | P-valuea | |||
|---|---|---|---|---|---|
| Total | Before biologic use (Control interval) |
During biologic use (Exposure interval) |
|||
| Asthma exacerbations | |||||
| All biologics (n = 355; before biologic use: 355.0 person-y, during biologic use: 447.9 person-y) |
270.5 | 337.4 | 217.5 | 0.68 (0.62–0.74) | <.001 |
| Omalizumab (n = 119; before biologic use: 119.0 person-y, during biologic use: 188.3 person-y) |
298.1 | 397.5 | 235.2 | 0.65 (0.55–0.77) | <.001 |
| Mepolizumab (n = 82; before biologic use: 82.0 person-y, during biologic use: 120.3 person-y) |
252.2 | 337.8 | 193.8 | 0.66 (0.57–0.76) | <.001 |
| Benralizumab (n = 69; before biologic use: 69.0 person-y, during biologic use: 71.3 person-y) |
303.0 | 362.3 | 245.6 | 0.67 (0.56–0.81) | <.001 |
| Dupilumab (n = 85; before biologic use: 85.0 person-y, during biologic use: 68.0 person-y) |
209.8 | 232.9 | 180.8 | 0.86 (0.73–0.99) | .048 |
| Hospitalizations | |||||
| All biologics (n = 355; before biologic use: 355.0 person-y, during biologic use: 447.9 person-y) |
20.7 | 25.9 | 16.5 | 0.65 (0.55–0.77) | <.001 |
| Omalizumab (n = 119; before biologic use: 119.0 person-y, during biologic use: 188.3 person-y) |
26.7 | 31.8 | 23.9 | 0.82 (0.60–1.12) | .21 |
| Mepolizumab (n = 82; before biologic use: 82.0 person-y, during biologic use: 120.3 person-y) |
15.8 | 23.2 | 10.8 | 0.64 (0.45–0.89) | .009 |
| Benralizumab (n = 69; before biologic use: 69.0 person-y, during biologic use: 71.3 person-y) |
20.0 | 27.5 | 12.6 | 0.45 (0.31–0.66) | <.001 |
| Dupilumab (n = 85; before biologic use: 85.0 person-y, during biologic use: 68.0 person-y) |
15.7 | 20.0 | 10.3 | 0.48 (0.33–0.69) | <.001 |
a
Conditional Poisson regression model including the logarithm of the interval time as the offset